Literature DB >> 2857749

Regulation of the growth of Epstein-Barr virus-infected B cells. I. Growth regression by E rosetting cells from VCA-positive donors is a combined effect of autologous mixed leukocyte reaction and activation of T8+ memory cells.

Y T Konttinen, H G Bluestein, N J Zvaifler.   

Abstract

Regression of B cell proliferation in co-cultures of EBV-infected B cells (BEBV) and autologous T cells at 1:4 ratio was studied. 3H-TdR incorporation was used to measure proliferation by the participating lymphocyte populations and a 51Cr release assay was used to document the generation of cells capable of killing autologous EBV-transformed B lymphoblastoid cell lines (LCLEBV). EBV-infected B cells cultured alone transformed to blasts by culture day 10, and continued to proliferate throughout the 22 day observation period. When EBV-infected B cells were co-cultured with E rosetted cells from VCA-positive donors, there was a characteristic proliferative response on day 10 (an augmented autologous mixed lymphocyte reaction; AMLR), followed by the development of T8+ cells capable of killing autologous LCLEBV, as well as over 90% suppression of EBV growth by day 22 as assessed by 3H-TdR incorporation, and confirmed in a visual outgrowth assay. Negative and positive selection techniques were used to define the regulatory components in the T cell population. Depletion of T8+ cells from the blood lymphocytes of VCA-positive donors did not significantly reduce the 10 day proliferative response, but the subsequent development of cytotoxic cells and the regression of BEBV outgrowth was not observed. Thus, the circulating T8+ cells are required for the subsequent appearance of autologous LCLEBV cytotoxicity and BEBV growth regulation. However, when the responder population consisted only of T8+ cells, the augmented AMLR response was absent, cytotoxic cell development was weak or absent, and there was no regression of EBV outgrowth. Therefore, the cells participating in the AMLR, as well as T8+ memory cells from VCA-positive donors, are necessary for the control of the in vitro EBV infection. Growth regression is dependent on the proliferation of the regulatory T cells. Mitomycin C treatment of fresh E rosetting cells or those exposed to BEBV for up to 10 days in culture abrogates growth regression and the subsequent appearance of LCLEBV killer cells. However, E rosetting cells exposed to BEBV for 14 days or more already have developed the ability to kill LCLEBV and no longer need to proliferate to induce growth regression when cultured with newly infected BEBV. These results lend additional support to the view that the control of EBV-induced B cell expansion requires a AMLR-dependent clonal amplification of EBV-specific, T8+ cytotoxic cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2857749

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  S Nikiforow; K Bottomly; G Miller
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Expression of proteins encoded by Epstein-Barr virus trans-activator genes depends on the differentiation of epithelial cells in oral hairy leukoplakia.

Authors:  J Becker; U Leser; M Marschall; A Langford; W Jilg; H Gelderblom; P Reichart; H Wolf
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

3.  Epstein-Barr virus in peripheral blood is associated with response to rituximab therapy in rheumatoid arthritis patients.

Authors:  Heikki Valleala; Markku J Kauppi; Vesa-Petteri Kouri; Markku Korpela
Journal:  Clin Rheumatol       Date:  2015-06-16       Impact factor: 2.980

4.  Cellular immunohistopathology of acute, subacute, and chronic synovitis in rheumatoid arthritis.

Authors:  Y T Konttinen; V Bergroth; D Nordström; K Koota; B Skrifvars; G Hagman; C Friman; M Hämäläinen; P Slätis
Journal:  Ann Rheum Dis       Date:  1985-08       Impact factor: 19.103

5.  T cell cytotoxicity to Epstein-Barr virus infected B cells: comparison of patients with rheumatoid arthritis and their HLA identical siblings.

Authors:  V R Winrow; J Norton; E J Holborow; H E Stierle; A Young; J A Sachs
Journal:  Ann Rheum Dis       Date:  1988-04       Impact factor: 19.103

6.  The effects of Plasmodium falciparum malaria on immune control of B lymphocytes in Gambian children.

Authors:  H C Whittle; J Brown; K Marsh; M Blackman; O Jobe; F Shenton
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

7.  Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  Sarah Nikiforow; Kim Bottomly; George Miller; Christian Münz
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

8.  Dendritic cells initiate immune control of epstein-barr virus transformation of B lymphocytes in vitro.

Authors:  Kara Bickham; Kiera Goodman; Casper Paludan; Sarah Nikiforow; Ming Li Tsang; Ralph M Steinman; Christian Münz
Journal:  J Exp Med       Date:  2003-12-01       Impact factor: 14.307

9.  Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in acquired immune deficiency syndrome-related lymphoproliferative disorders. Implications for lymphomagenesis.

Authors:  P G Pelicci; D M Knowles; Z A Arlin; R Wieczorek; P Luciw; D Dina; C Basilico; R Dalla-Favera
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.